What are the recommended intravenous loading and maintenance doses of valproate for a 70‑kg adult and for children, and how should the dose be adjusted in hepatic impairment, elderly patients, or those with urea‑cycle disorders?

Valproate Intravenous Dosing

For a 70-kg adult with status epilepticus, administer an IV loading dose of 20-30 mg/kg (1400-2100 mg) infused at 3-6 mg/kg/min, followed by maintenance dosing of 1-3 mg/kg/hour; for children, use 20 mg/kg loading dose at the same infusion rate, with maintenance of 1-2 mg/kg/hour. 1, 2, 3

Adult Dosing (70-kg patient)

Loading Dose

• Standard loading: 20 mg/kg = 1400 mg for a 70-kg adult 1
• Higher loading: Up to 30 mg/kg (2100 mg) may be used in refractory cases 1, 4
• Infusion rate: 3-6 mg/kg/min (maximum 40 mg/min per FDA label) 1, 3
• Expected peak concentration: 65-80 mg/L total, 7.5-11 mg/L free 5

The most recent high-quality evidence from the ESETT trial 2 demonstrated that valproate 30 mg/kg IV load delivered at 5 mg/kg/min achieved seizure cessation in 46% of benzodiazepine-refractory status epilepticus cases, with similar efficacy to levetiracetam and fosphenytoin.

Maintenance Dosing

• Standard maintenance: 1-3 mg/kg/hour continuous infusion 1
• Alternative: 6 mg/kg every 6 hours 5, 6
• Target therapeutic range: 50-100 mg/L total concentration 5

Pediatric Dosing

Loading Dose

• Standard: 20 mg/kg IV 7, 8, 3
• Maximum initial dose: 1000 mg 7
• Infusion time: 10-20 minutes; not to exceed 1 mg/kg/min 7
• Expected peak: ~75 mg/L after 20 mg/kg load 6

Maintenance Dosing

• Non-induced children: 1-2 mg/kg/hour continuous infusion 6
• Alternative: 6 mg/kg every 6 hours 6, 9
• Children on enzyme inducers: May require 4-6 mg/kg/hour due to 2.5-fold increased clearance 6

Critical consideration: Pediatric patients ages 3 months to 10 years have 50% higher weight-adjusted clearance than adults, necessitating higher maintenance doses 3.

Special Population Adjustments

Hepatic Impairment

• Contraindication: Valproate is absolutely contraindicated in severe hepatic disease 3
• Mild-moderate impairment: Reduce initial dose; clearance decreased by 16-50% 3
• Monitoring: Free (unbound) concentrations increase 2-2.6 fold; total concentrations may appear falsely normal 3
• Clinical implication: Monitor free valproate levels, not total levels, as protein binding is substantially reduced 3

Elderly Patients

• Dose reduction required: Initial dosage should be reduced 3
• Pharmacokinetic changes: 39% reduction in intrinsic clearance, 44% increase in free fraction 3
• Practical approach: Start with lower end of dosing range (15 mg/kg loading, 1 mg/kg/hour maintenance) 10
• Protein binding: Decreases from 10% free at low concentrations to 17.4% at higher concentrations in elderly 10

Urea Cycle Disorders

• Absolute contraindication: Valproate is contraindicated in patients with known or suspected urea cycle disorders 3
• Risk: Can precipitate fatal hyperammonemic encephalopathy 11, 3
• If hyperammonemia develops: Immediately discontinue valproate and initiate nitrogen-scavenging therapy 11
  • Sodium benzoate: 250 mg/kg (if <20 kg) or 5.5 g/m² (if >20 kg) IV over 90 min 11
  • L-arginine: 200-600 mg/kg depending on specific enzyme deficiency 11

Renal Impairment

• Mild reduction in clearance: 27% decrease in unbound clearance with CrCl <10 mL/min 3
• No dose adjustment typically needed: Protein binding substantially reduced, so monitor free concentrations 3
• Hemodialysis: Reduces valproate concentrations by ~20% 3

Infusion Rate and Safety

Rapid Administration

• Standard rate: 3-6 mg/kg/min is well-tolerated 1, 4
• Faster rates: Up to 10 mg/kg/min (30 mg/kg at this rate) showed good tolerability in systematic review 4
• Recent evidence: Undiluted IV push at 500 mg/min demonstrated favorable safety profile across >5500 doses, including loading doses up to 4000 mg 12, 13

Adverse Effects

• Cardiovascular: Hypotension rare (0-12% in trials), significantly less than phenytoin 1, 2
• Respiratory: Minimal respiratory depression, unlike barbiturates 4
• Thrombocytopenia: Occurs in <10% of cases 1
• Hyperammonemia: Most serious concern; can cause acute encephalopathy even without hepatic dysfunction 3, 4, 14, 15
• Hepatotoxicity: Type I (dose-dependent, reversible) and Type II (idiosyncratic, potentially fatal) 14, 15

Clinical Pearls

Enzyme induction status matters: Patients on carbamazepine, phenytoin, or phenobarbital clear valproate 2.5 times faster and require doubled maintenance doses 3, 6.

Protein binding is concentration-dependent: Free fraction increases from 10% at 40 mcg/mL to 18.5% at 130 mcg/mL, making dose-concentration relationships nonlinear 3.

Neonates have markedly impaired clearance: Half-life ranges 10-67 hours in infants <10 days old versus 7-13 hours in children >2 months; use extreme caution 3.

Therapeutic equivalence: Valproate performs similarly to phenytoin/fosphenytoin for benzodiazepine-refractory status epilepticus but can be administered more rapidly with fewer cardiovascular adverse effects 1, 2.